Avidity Biosciences Inc [RNA] stock is trading at $26.66, up 3.49%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RNA shares have gain 10.58% over the last week, with a monthly amount drifted -15.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $70. Previously, BMO Capital Markets started tracking the stock with Outperform rating on March 12, 2025, and set its price target to $72. On March 07, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $70 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $72 on December 20, 2024. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $67 as its price target on November 26, 2024. Goldman started tracking with a Buy rating for this stock on September 24, 2024, and assigned it a price target of $59. In a note dated August 28, 2024, Barclays initiated an Overweight rating and provided a target price of $63 on this stock.
Avidity Biosciences Inc [RNA] stock has fluctuated between $21.51 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $54.5 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $26.66 at the most recent close of the market. An investor can expect a potential return of 104.43% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.90M for the trailing twelve months, which represents a growth of 35.57%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -34.77%, Pretax Profit Margin comes in at -29.58%, and Net Profit Margin reading is -29.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.26 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.87 points at the first support level, and at 25.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.23, and for the 2nd resistance point, it is at 27.81.
Ratios To Look Out For
For context, Avidity Biosciences Inc’s Current Ratio is 15.73. In addition, the Quick Ratio stands at 15.73 and the Cash Ratio stands at 2.24. Considering the valuation of this stock, the price to sales ratio is 294.02, the price to book ratio is 2.24.
Transactions by insiders
Recent insider trading involved Gallagher Kathleen P., Chief Program Officer, that happened on Apr 01 ’25 when 5875.0 shares were sold. Chief Medical Officer, Hughes Steven George completed a deal on Mar 20 ’25 to sell 9578.0 shares. Meanwhile, President and CEO Boyce Sarah sold 31540.0 shares on Mar 20 ’25.
